Small cell ovarian carcinoma: Genomic stability and responsiveness to therapeutics

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Gamwell, Lisa F ^a,b   Gambaro, Karen ^c   Merziotis, Maria ^b   Crane, Colleen ^b   Arcand, Suzanna L ^d   Bourada, Valerie ^a,b   Davis, Christopher ^b   Squire, Jeremy A ^e   Huntsman, David G ^f,g   Tonin, Patricia N ^c,d   Vanderhyden, Barbara C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

BIN 67; Cell line; Genomic anomalies; Immunohistochemistry; Small cell ovarian cancer

Indexed keywords

B RAF KINASE; CARBOPLATIN; CISPLATIN; DNA; K RAS PROTEIN; ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; PROTEIN P53; VIMENTIN; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER RESISTANCE; CARCINOGENESIS; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HYPERCALCEMIA; IN VITRO STUDY; KARYOTYPE; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL CELL CARCINOMA; SMALL CELL OVARIAN CARCINOMA OF THE HYPERCALCEMIC TYPE; SOMATIC MUTATION; SPHEROID CELL; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMANS; KARYOTYPING; MICE; MUTATION; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874001468     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-33     Document Type: Article

References (59)

1. Small cell carcinoma of the ovary with hypercalcemia: a report of eleven cases. Dickersin GR, Kline IW, Scully RE, Cancer 1982 49 188 197 10.1002/1097-0142(19820101)49:1<188::AID-CNCR2820490137>3.0.CO;2-D 6274502 (Pubitemid 12196156)
2. Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions. Clement PB, Mod Pathol 2005 18 113 S129 15492757
3. Small cell ovarian carcinoma: a rare, aggressive tumor masquerading as constipation in a teenager with a fatal outcome. Barondeau J, Rodgers M, Braun L, Azarow K, Forouhar M, Faucette M, J Pediatr Hematol Oncol 2010 32 139 141 10.1097/MPH.0b013e3181bdbc8d 20057325
4. Familial small cell carcinoma of the ovary. Martinez-Borges AR, Petty JK, Hurt G, Striblin JT, Press JZ, Castelinno SM, Pediatr Blood Cancer 2009 53 1334 1336 10.1002/pbc.22184 19621450
5. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Young RH, Oliva E, Scully RE, Am J Surg Pathol 1994 18 1102 1116 10.1097/00000478-199411000-00004 7943531 (Pubitemid 24337617)
6. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Pautier P, Ribrag V, Duvillard P, Rey A, Elghissassi I, Sillet-Bach I, Kerbrat P, Mayer F, Lesoin A, Brun B, Crouet H, Barats JC, Morice P, Lhommé C, Ann Oncol 2007 18 1985 1989 10.1093/annonc/mdm376 17761699 (Pubitemid 350286236)
7. Uterine and ovarian conservation in advanced small cell carcinoma of the ovary. Powell JL, McAfee RD, McCoy RC, Shiro BS, Obstet Gynecol 1998 91 846 848 10.1016/S0029-7844(98)00025-8 9572186 (Pubitemid 28186101)
8. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Carlson JW, Nucci MR, Brodsky J, Crum CP, Hirsch MS, Histopathology 2007 51 305 312 10.1111/j.1365-2559.2007.02790.x 17727473 (Pubitemid 47301628)
9. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. McCluggage WG, Oliva E, Connolly LE, McBride HA, Young RH, Int J Gynecol Pathol 2004 23 330 336 10.1097/01.pgp.0000139644.38835.9d 15381902 (Pubitemid 39299021)
10. Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: a calcitonin-responsive line derived from a rare tumor type. Upchurch KS, Parker LM, Scully RE, Krane SM, J Bone Miner Res 1986 1 299 304 2845729
11. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH, Cytokine Growth Factor Rev 2010 21 85 89 10.1016/j.cytogfr.2010.02.001 20472490
12. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC, Mol Ther 2012 Epub ahead of print
13. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell JC, Kirn DH, J Clin Invest 2007 117 3350 3358 10.1172/JCI32727 17965776 (Pubitemid 350096991)
14. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J, Proc Natl Acad Sci USA 2008 105 14981 14986 10.1073/pnas.0803988105 18815361
15. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC, Exp Cell Res 2007 313 133 145 10.1016/j.yexcr.2006. 09.026 17070800 (Pubitemid 44958459)
16. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF, Cancer Res 1985 45 2110 2115 3986765 (Pubitemid 15024393)
17. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM, Molec Carcinogen 2007 46 872 885 10.1002/mc.20315 (Pubitemid 47549773)
18. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN, PLoS One 2011 6 28250 10.1371/journal.pone.0028250 22163003
19. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG, N Engl J Med 2012 366 234 242 10.1056/NEJMoa1102903 22187960
20. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S, METABRIC Group, Nature 2012 486 346 352 22522925
21. Circos: an information aesthetic for comparative genomics. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA, Genome Res 2009 19 1639 1645 10.1101/gr.092759.109 19541911
22. Hidden chromosome abnormalaties in haematological malignancies detected by multicolour spectral karyotyping. Veldman T, Vignon C, Schröck E, Rowley JD, Ried T, Nat Genet 1997 15 406 410 9090389 (Pubitemid 27147112)
23. Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN, Mol Carcinog 2004 41 17 38 10.1002/mc.20038 15352123 (Pubitemid 39195598)
24. Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. Cody N, Zietarska M, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN, BMC Med Genomics 2008 1 34 10.1186/1755-8794-1-34 18687136
25. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J, Am J Pathol 1999 155 711 715 10.1016/S0002-9440(10)65169-3 10487828 (Pubitemid 29426816)
26. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. McCluggage WG, Kennedy K, Busam KJ, Am J Surg Pathol 2010 34 525 532 10.1097/PAS.0b013e3181d1d457 20182342
27. Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia. Nagasaki K, Otsubo K, Kajimura N, Tanaka R, Watanabe H, Tachimori Y, Kato H, Yamaguchi H, Saito D, Watanabe T, Adachi I, Yamaguchi K, Jpn J Clin Oncol 1996 26 6 11 10.1093/oxfordjournals.jjco.a023180 8551669 (Pubitemid 126469259)
28. Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. Tsunematsu T, Saito T, Iguchi H, Fukuda T, Tsukamoto N, Gynecol Oncol 2000 76 218 222 10.1006/gyno.1999.5619 10637074 (Pubitemid 30067199)
29. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, Hudson PJ, Martin TJ, Wood WI, Science 1987 237 893 896 10.1126/science.3616618 3616618 (Pubitemid 17128278)
30. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Milstone L, Barton DE, Francke U, Broadus AE, Proc Natl Acad Sci USA 1988 85 597 601 10.1073/pnas.85.2.597 2829195
31. Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network, Nature 2011 474 609 615 10.1038/nature10166 21720365
32. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IM, Am J Surg Pathol 2005 29 218 224 10.1097/01.pas.0000146025.91953.8d 15644779 (Pubitemid 40170640)
33. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J, Cancer 1997 79 1581 1586 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID- CNCR21>3.0.CO;2-T 9118042 (Pubitemid 27154791)
34. Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Schuyer M, Henzen-Logmans SC, Van der Burg ME, Fieret JH, Derksen C, Look MP, Meijer-van Gelder ME, Klijn JG, Foekens JA, Berns EM, Eur J Obstet Gynecol Reprod Biol 1999 82 147 150 10.1016/S0301-2115(98)00217-6 10206406 (Pubitemid 29074310)
35. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Tse W, Zhu W, Chen HS, Cohen A, Blood 1995 85 650 656 7833468
36. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y, Reynier P, J Clin Endocrinol Metab 2005 90 2314 2320 10.1210/jc.2004-1337 15623817 (Pubitemid 40586279)
37. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, Ou ZL, Shen ZZ, Ding J, Shao ZM, Eur J Cancer 2006 42 3274 3286 10.1016/j.ejca.2006.07.008 16979889 (Pubitemid 44872944)
38. Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. Chaib H, Rubin MA, Mucci NR, Li L, Taylor JMG, Day ML, Rhim JS, Macoska JA, Cancer Res 2001 61 2390 2394 11289102 (Pubitemid 32685811)
39. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53. Tam CW, Liu VW, Leung WY, Yao KM, Shiu SY, Cancer Lett 2008 271 64 80 10.1016/j.canlet.2008.05.047 18639375
40. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L, Nature 2009 459 1085 1090 10.1038/nature08109 19553991
41. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N, Trends Endocrinol Metab 2010 21 691 698 10.1016/j.tem.2010.08.004 20846877
42. Prolactin increases survival and migration of ovarian cancer cells: Importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. Tan D, Chen KE, Khoo T, Walker AM, Cancer Lett 2011 310 101 108 10.1016/j.canlet.2011.06.014 21775057
43. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Frescas D, Pagano M, Nat Rev Cancer 2008 8 438 449 10.1038/nrc2396 18500245 (Pubitemid 351744963)
44. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Uddin S, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, Bavi P, Al-Kuraya KS, Lab Invest 2009 89 1115 1127 10.1038/labinvest.2009.75 19636294
45. Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O, Histopathology 2010 56 740 749 10.1111/j.1365-2559.2010.03551.x 20546339
46. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Shigemasa K, Gu L, O'Brien TJ, Ohama K, Clin Cancer Res 2003 9 1756 1763 12738731 (Pubitemid 36554601)
47. Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M, Oncol Rep 2006 15 765 771 16525656
48. A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. He N, Jahchan NS, Hong E, Li Q, Bayfield MA, Maraia RJ, Luo K, Zhou Q, Mol Cell 2008 29 588 599 10.1016/j.molcel.2008.01.003 18249148
49. Regulation of larval hematopoiesis in Drosophila melanogaster: a role for the multi sex combs gene. Remillieux-Leschelle N, Santamaria P, Randsholt NB, Genetics 2002 162 1259 1274 12454071 (Pubitemid 35417517)
50. Advanced-stage small cell carcinoma of the ovary in pregnancy: long-term survival after surgical debulking and multiagent chemotherapy. Tewari K, Brewer C, Cappuccini F, Macri C, Rogers LW, Berman ML, Gynecol Oncol 1997 66 531 534 10.1006/gyno.1997.4801 9299272 (Pubitemid 27388150)
51. Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy. Rana S, Warren BK, Yamada SD, Obstet Gynecol 2004 103 1120 1123 10.1097/01.AOG.0000124996.56880.d9 15121630
52. Small cell of the ovary, hypercalcemic type-analysis of combined experience and recommendation for management. A GCIG study. Harrison ML, Hoskins P, du Bois A, Quinn M, Rustin GJ, Ledermann JA, Baron-Hay S, Friedlander ML, Gynecol Oncol 2006 100 233 238 10.1016/j.ygyno.2005.10.024 16321429 (Pubitemid 43075255)
53. Oncolytic viruses: what's next? Bell JC, Curr Cancer Drug Targets 2007 7 127 131 10.2174/156800907780058844 17346103 (Pubitemid 46348626)
54. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Crompton AM, Kirn DH, Curr Cancer Drug Targets 2007 7 133 139 10.2174/156800907780058862 17346104 (Pubitemid 46348627)
55. Recent progress in the battle between oncolytic viruses and tumours. Parato KA, Senger D, Forsyth PA, Bell JC, Nat Rev Cancer 2005 5 965 976 16294217 (Pubitemid 41766784)
56. Interferons, immunity and cancer immunoediting. Dunn GP, Koebel CM, Schreiber RD, Nat Rev Immunol 2006 6 836 848 10.1038/nri1961 17063185 (Pubitemid 44631652)
57. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC, Hum Gene Ther 2004 15 821 831 10.1089/hum.2004.15. 821 15353037 (Pubitemid 39244837)
58. Hypercalcemic-type of small cell carcinoma of the ovary: characterization of a new tumor line. Walt H, Hornung R, Fink D, Dobler-Girdziunaite D, Stallmach T, Spycher MA, Maly F, Haller U, Bürki N, Anticancer Res 2001 21 3253- 3259 11848480
59. Establishment and characterization of a human ovarian small cell carcinoma, hypercalcemic type, cell line (OS-1) secreting PTH, PthrP and ACTH-special reference to the susceptibility of anti-cancer drugs. Ohi S, Niimi S, Okada N, Yamada K, Tachibana T, Hashimoto H, Nakajima M, Yasuda M, Tanaka T, Sato K, Ishikawa H, Hum Cell 2004 17 203 209 16035505